Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. on February 9, 2021. The report discloses corporate governance updates, specifically regarding executive compensation amendments and the scheduling of the 2021 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes
- Executive Compensation: The Board approved amendments to the Change in Control and Severance Agreements for CEO Christian Henry and CFO Susan Kim. The new terms add a lump-sum cash payment equal to the annualized target bonus (pro-rated) if termination occurs without cause or resignation for good reason within 12 months of a change in control.
- Annual Meeting Date: The 2021 Annual Meeting is scheduled for June 16, 2021, with a record date of April 19, 2021.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure that the summary of severance agreements is qualified by the full text of the agreements to be filed in the 2020 Form 10-K.
Investor Verification Checklist
- Verify the full text of the amended Severance Agreements in the upcoming 2020 Form 10-K to understand total potential liability.
- Confirm the deadlines for stockholder proposals: February 24, 2021, for inclusion in proxy materials.
- Note the window for stockholder nominations: between February 16, 2021, and March 18, 2021.
- Check the record date of April 19, 2021, to determine eligibility to vote at the June 16, 2021, meeting.